Hatteras Venture Partners

Hatteras Venture Partners

U.S.-based venture capital firm specializing in funding startups in the medical industry operating from the Southeastern states.

Hatteras Venture Partners is a venture capital firm established in 2000. The firm was founded by Clay B. Thorp and John Crumpler. It operates from its headquarters in Durham, North Carolina. As of March 2019, the firm has 44 active companies in its portfolio and has sold off its ownership in 35 companies. It has most recently invested in Kymera on November 2018, a company specializing in the development of biotechnology to treat untreatable diseases.

Hatteras Venture Partners’ primary investment focus is in companies providing products and services in the field of biopharmaceuticals, medical devices, diagnostic, healthcare information technology and medicine sectors. The firm funds companies in various stages of development, from early stage to mid-venture. It prefers to fund companies operating from the Southeastern states of the U.S., such as North Carolina. Its latest funding round was held in January 2017, which managed to amass a total of $150 million.

Timeline

Funded Companies

Company
Description
Website
Industry
Location

Orig3n is a biotechnology company developing personalized regenerative medicine treatments based on patient genetic profiles.

Rodin Therapeutics is a biotechnology company developing treatments for Alzheimer's disease that is headquartered in Cambridge, Massachusetts and was founded in 2013 by Ankit Mahadevia and Martin Jefson.

SugarSync is a San Mateo, California-based file sharing company.

A clinical research organization that gives services to rising pharmaceutical, biotechnology and medical device companies

Wildflower Health is a San Francisco-based company founded by Leah Sparks.

A biopharmaceutical company that develops drugs for the treatment of cardiovascular diseases, endocrine and other metabolic disorders

A company developing opthalmic therapeutic products

A pharmaceutical company developing therapies for ocular diseases

StrideBio, Inc. is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies.

A company developing molecular diagnostic assays and drugs for the treatment of cancer

A company developing antifungal therapies

Coferon develops therapeutic molecules

22 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Dana Fowlkes

Venture Partner

Fred Goldwater

Venture Partner

Andrew Guo

Employee

Christy L. Shaffer

Venture Partner

Clay B. Thorp

Founder/General Partner

Jeff Terrell

Employee

John Crumpler

Founder/General Partner

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

GeneCentric

Respirics

Stridebio

Trefoil Therapeutics

Viamet

Wildflower

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.